These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 37155984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B, Hwang YJ, Selvin E, Jameson BC, Chang AR, Grams ME, Shin JI.
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH.
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun 21; 9(4):397-407. PubMed ID: 35797996
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A, Shoji S, Kosakai Y, Koga T, Asakawa K, Rokuda M.
    J Diabetes Investig; 2023 Mar 21; 14(3):404-416. PubMed ID: 36515129
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
    Htoo PT, Buse J, Cavender M, Wang T, Pate V, Edwards J, Stürmer T.
    J Am Heart Assoc; 2022 Feb 15; 11(4):e022376. PubMed ID: 35132865
    [Abstract] [Full Text] [Related]

  • 14. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 15. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY, Yang CT, Kuo S, Wu CH, Lin WH, Ou HT.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246928. PubMed ID: 36520437
    [Abstract] [Full Text] [Related]

  • 16. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
    Yang JY, Moon AM, Kim H, Pate V, Barritt AS, Crowley MJ, Buse JB, Stürmer T, Alexopoulos AS.
    J Diabetes Complications; 2020 Nov 01; 34(11):107706. PubMed ID: 32843283
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.
    Ko HY, Bea S, Jeong HE, Park S, Cho YM, Kong SH, Shin JY.
    JAMA Netw Open; 2023 Sep 05; 6(9):e2335797. PubMed ID: 37751205
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.